Autor: Jose Viña y Mari Carmen Gomez-Cabrera
|Nuria Garatachea & Alejandro Lucía, (2011). Genes and the ageing muscle: a review on genetic
Western populations are living longer. Ageing decline in muscle mass and strength (i.e.
sarcopenia) is becoming a growing public health problem, as it contributes to the decreased capacity
for independent living. It is thus important to determine those genetic factors that interact with ageing and thus modulate functional capacity and skeletal muscle phenotypes in older people. It would be also clinically relevant to identify ‘unfavourable’ genotypes associated with accelerated sarcopenia. In this
review, we summarized published information on the potential associations between some genetic polymorphisms andmuscle phenotypes in older people.Aspecial emphasis was placed on those candidate polymorphisms that have beenmore extensively studied, i.e. angiotensinconverting enzyme (ACE) gene I/D, α-actinin-3 (ACTN3) R577X, and myostatin (MSTN) K153R, among others. Although previous heritability studies have indicated that there is an important genetic contribution to individual variability in muscle phenotypes among old people, published data on specific gene variants are controversial. The ACTN3 R577X polymorphism could influence muscle function in old women, yet there is controversy with regards to which allele (R or X) might play a ‘favourable’ role. Though more research is needed, up-to-date MSTN genotype is possibly the strongest candidate to explain variance among muscle phenotypes in the elderly. Future studies should take into account the association between muscle phenotypes in this population and complex gene–gene and gene–environment interactions.
|Todd M. Manini, and Brian C. Clark, (2012). Dynapenia and Aging: An Update.
In 2008, we published an article arguing that the age-related loss of muscle strength is only partially explained by the reduction in muscle mass and that other physiologic factors explain muscle weakness in older adults (Clark BC, Manini TM. Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci. 2008;63:829–834). Accordingly, we proposed that these events (strength and mass loss) be defined independently, leaving the term “sarcopenia” to be used in its original context to describe the age-related loss of muscle mass. We subsequently coined the term “dynapenia” to describe the age-related loss of muscle strength and power. This article will give an update on both the biological and clinical literature on dynapenia—
serving to best synthesize this translational topic. Additionally, we propose a working decision algorithm for defining dynapenia. This algorithm is specific to screening for and defining dynapenia using age, presence or absence of risk factors, a grip strength screening, and if warranted a test for knee extension strength. A definition for a single risk factor such as dynapenia will provide information in building a risk profile for the complex etiology of physical disability. As such, this approach mimics the development of risk profiles for cardiovascular disease that include such factors as hypercholesterolemia, hypertension, hyperglycemia, etc. Because of a lack of data, the working decision algorithm remains
to be fully developed and evaluated. However, these efforts are expected to provide a specific understanding of the role that dynapenia plays in the loss of physical function and increased risk for disability among older adult
|Francesco Landi, Rosa Liperoti,Domenico Fusco, Simona Mastropaolo, Davide Quattrociocchi,Anna Proia, Andrea Russo,Roberto Bernabei,and Graziano Onder, (2012).Prevalence and Risk Factors of Sarcopenia Among Nursing Home Older Residents.
Sarcopenia has been indicated as a reliable marker of frailty and poor prognosis among the oldest individuals. At present, there are no data on sarcopenia in nursing home population. We evaluated the prevalence of sarcopenia and its association with functional and clinical status in a population of elderly persons aged 70 years and older living in nursing homes.
|Christy S. Carter,Emanuele Marzetti, Christiaan Leeuwenburgh,Todd Manini, Thomas C. Foster, Leanne Groban,Philip J. Scarpace, and Drake Morgan, (2012).Usefulness of Preclinical Models for Assessing the Efficacy of Late-Life Interventions for Sarcopenia.
Caloric restriction and physical exercise have proven beneficial against age-associated changes in body composition and declining physical performance; however, little is known regarding what benefit these interventions might have when initiated late in life. The study of mimetics of diet and exercise and the combination thereof may provide additional treatments
for a vulnerable elderly population; however, how and when to initiate such interventions requires consideration in developing the most safe and efficacious treatment strategies. In this review, we focus on preclinical late-life intervention studies, which assess the relationship between physical function, sarcopenia, and body composition. We provide a conceptual
framework for the ever-changing definition of sarcopenia and a rationale for the use of an appropriate rodent model of this condition. We finish by providing our perspective regarding the implications of this body of work and future areas of research that may also contribute to the ultimate goal of extending healthspan.
|1. Balagopal P, Schimke JC, Ades P, Adey D & Nair KS. (2001). Age effect on transcript levels and synthesis rate of muscle MHC and response to resistance exercise. Am J Physiol Endocrinol Metab 280, E203-208. Free Text|
|2. Bua E, Johnson J, Herbst A, Delong B, McKenzie D, Salamat S & Aiken JM. (2006). Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers. Am J Hum Genet 79, 469-480. Free Text|
|3. Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ & Shoelson SE. (2004). IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119, 285-298.|
|4. Castillo EM, Goodman-Gruen D, Kritz-Silverstein D, Morton DJ, Wingard DL & Barrett-Connor E. (2003). Sarcopenia in elderly men and women: the Rancho Bernardo study. Am J Prev Med 25, 226-231.|
|5. Colman JC, Morgan NY, Scheuer PJ & Sherlock S. (1980). Treatment of alcohol-related liver disease with (+)-cyanidanol-3: a randomized double-blind trial. Gut 21, 965-969. Free Text|
|6. Doherty TJ. (2003). Invited review: Aging and sarcopenia. J Appl Physiol 95, 1717-1727. Free Text|
|7. Figueiredo PA, Powers SK, Ferreira RM, Appell HJ & Duarte JA. (2009). Aging impairs skeletal muscle mitochondrial bioenergetic function. J Gerontol A Biol Sci Med Sci 64, 21-33. Free Text|
|8. Greiwe JS, Cheng B, Rubin DC, Yarasheski KE & Semenkovich CF. (2001). Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. Faseb J 15, 475-482. Free Text|
|9. Hacker TA, McKiernan SH, Douglas PS, Wanagat J & Aiken JM. (2006). Age-related changes in cardiac structure and function in Fischer 344 x Brown Norway hybrid rats. Am J Physiol Heart Circ Physiol 290, H304-311. Free Text|
|10. Hakimi P, Yang J, Casadesus G, Massillon D, Tolentino-Silva F, Nye CK, Cabrera ME, Hagen DR, Utter CB, Baghdy Y, Johnson DH, Wilson DL, Kirwan JP, Kalhan SC & Hanson RW. (2007). Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem 282, 32844-32855. Free Text|
|11. Harman D. (1956). Aging: a theory based on free radical and ratiation chemistry. J Gerontol 11, 298-300.|
|12. Janssen YMW, Van Houten B, Borm PAJ & Mossman BT. (1993). Biology of disease: Cell and tissue responses to oxidative damage. Lab Invest 69, 261-274.|
|13. Ji LL, Gomez-Cabrera MC & Vina J. (2009). Role of free radicals and antioxidant signaling in skeletal muscle health and pathology. Infect Disord Drug Targets 9, 428-444.|
|14. Johnson JE, Mehler WR & Miquel J. (1975). A fine structural study of degenerative changes in the dorsal column nuclei of aging mice. Lack of protection by vitamin E. J Gerontol 30, 395-411.|
|15. Johnston AP, De Lisio M & Parise G. (2008). Resistance training, sarcopenia, and the mitochondrial theory of aging. Appl Physiol Nutr Metab 33, 191-199.|
|16. Lee CE, McArdle A & Griffiths RD. (2007). The role of hormones, cytokines and heat shock proteins during age-related muscle loss. Clin Nutr 26, 524-534.|
|17. Leger B, Derave W, De Bock K, Hespel P & Russell AP. (2008). Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 11, 163-175B.|
|18. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R & Spiegelman BM. (2002). Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418, 797-801.|
|19. Lopez-Lluch G, Irusta PM, Navas P & de Cabo R. (2008). Mitochondrial biogenesis and healthy aging. Exp Gerontol 43, 813-819. Free Text|
|20. Marzetti E, Wohlgemuth SE, Lees HA, Chung HY, Giovannini S & Leeuwenburgh C. (2008). Age-related activation of mitochondrial caspase-independent apoptotic signaling in rat gastrocnemius muscle. Mech Ageing Dev 129, 542-549.|
|21. Melov S, Tarnopolsky MA, Beckman K, Felkey K & Hubbard A. (2007). Resistance exercise reverses aging in human skeletal muscle. PLoS ONE 2, e465. Free Text|
|22. Melton LJ, 3rd, Khosla S, Crowson CS, O'Connor MK, O'Fallon WM & Riggs BL. (2000). Epidemiology of sarcopenia. J Am Geriatr Soc 48, 625-630.|
|23. Miquel J, Economos AC, Fleming J & Johnson JE, Jr. (1980). Mitochondrial role in cell aging. Exp Gerontol 15, 575-591.|
|24. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL & Rosenthal N. (2001). Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27, 195-200.|
|25. Navarro A & Boveris A. (2007). The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol 292, C670-686. Free Text|
|26. Potthoff MJ, Olson EN & Bassel-Duby R. (2007). Skeletal muscle remodeling. Curr Opin Rheumatol 19, 542-549.|
|27. Puigserver P & Spiegelman BM. (2003). Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24, 78-90.Free Text|
|28. Puigserver P, Wu Z, Park CW, Graves R, Wright M & Spiegelman BM. (1998). A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829-839.|
|29. Reid MB & Li YP. (2001). Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2, 269-272. Free Text|
|30. Reznick RM, Zong H, Li J, Morino K, Moore IK, Yu HJ, Liu ZX, Dong J, Mustard KJ, Hawley SA, Befroy D, Pypaert M, Hardie DG, Young LH & Shulman GI. (2007). Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab 5, 151-156. Free Text|
|31. Sies H. (1985). Oxidative stress. London: Academic. No Funciona|
|32. Sies H & Cadenas E. (1985). Oxidative stress: damage to intact cells and organs. Philos Trans R Soc Lond B Biol Sci 311, 617-631.|
|33. Vasilaki A, McArdle F, Iwanejko LM & McArdle A. (2006). Adaptive responses of mouse skeletal muscle to contractile activity: The effect of age. Mech Ageing Dev 127, 830-839.|
|34. Vina J, Gomez-Cabrera MC, Borras C, Froio T, Sanchis-Gomar F, Martinez-Bello VE & Pallardo FV. (2009). Mitochondrial biogenesis in exercise and in ageing. Adv Drug Deliv Rev 61, 1369-1374.|